AstraZeneca, the Anglo-Swedish pharmaceutical company, has bought Pearl Therapeutics for up to $1.15bn as it seeks to revive its drug development pipeline after being badly hit by patent expiries. Lex writers Oliver Ralph and Vincent Boland consider whether the deal will help AstraZeneca to achieve its aims.
For more video content from the Financial Times, visit http://www.FT.com/video
